Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Versus Continuous HAART (Highly Active Antiretroviral Therapy) for Treating Chronic HIV Infected Patients in Uganda

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Documentation of HIV-1 infection by licensed ELISA test kit and confirmed by a second method (e.g. Western Blot).~Absolute CD4+ T-cell count of greater than or equal to 125/mm(3) within 30 days before randomization (For patients who are status post-splenectomy, also CD4+ T-cell greater than 20%).~If the CD4+ T cell count is less than or equal to 200 cells/mm(3), the patient must be receiving PCP prophylaxis.~Receiving at least 3-drug HAART with the most recent viral load test prior to screening less than 500 copies/ml. Patients must be receiving 3 drug HAART containing an NNRTI, abacavir or PI for at least 90 days prior to enrollment and at least 1 PI or efavirenz for 30 days prior to enrollment.~A viral load of less than 50 copies/ml prior to enrollment.~Age at least 18 years and above.~For women of childbearing potential, a negative pregnancy test (serum or urine) is required within 14 days prior to randomization.~Laboratory values (within 30 days prior to randomization):~1. AST no more than 5 X the upper limit of normal (ULN).~2. Total or direct bilirubin no more than 2 X ULN unless there is a pattern consistent with Gilbert s syndrome or the patient is receiving indinavir.~3. Creatinine no more than 2.0 mg/dL.~4. Platelet count at least 50,000/microliters.~Written consent to participate in the trial.~Patient financially capable of purchasing the drugs uninterrupted for at least 72 weeks (the duration of the study).~EXCLUSION CRITERIA:~Concurrent malignancy, or any other disease state, requiring cytotoxic chemotherapy.~Symptomatic for significant HIV-related illnesses, such as opportunistic infections and malignancies other than mucocutaneous Kaposi s sarcoma. A history of AIDS defining opportunistic infections other than mucocutaneous Kaposi s sarcoma or candida or treated tuberculosis.~Use of experimental antiretroviral less than or equal to 6 months prior to enrollment. An exception may be made for hydroxeurea according to the judgment of the Principal Investigator.~Pregnancy or breastfeeding.~Significant cardiac, pulmonary, kidney, rheumatologic, gastrointestinal, or CNS disease as detectable on routine history, physical examination, or screening laboratory studies. If an abnormality is a contraindication to a specific drug, an alternative drug within the same class may be used.~Psychiatric illness that, in the opinion of the PI, might interfere with study compliance.~Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or compromise patient safety.~Refusal to practice safe sex or use precautions against pregnancy (effective birth control with barrier contraceptives or abstinence).~Known history or laboratory evidence of chronic hepatitis B infection including surface antigen positivity.~Receiving salvage HAART, i.e. evidence of clinical resistance to licensed anti-retrovirals as indicated by clinical progression, an elevated viral load or declining CD4+ T cell count while receiving antiretroviral therapy, or receiving sub-optimal antiretroviral therapy prior to HAART.~Patients currently receiving nevirapine or abacavir are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete